Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
复制标题
DOI：
10.1186/1472-6890-14-8
复制
发表时间：
2014-02-04
影响因子：
--
通讯作者：
Theocharis S
中科院分区：
文献类型：
--
作者：
Giaginis C;Tsoukalas N;Bournakis E;Alexandrou P;Kavantzas N;Patsouris E;Theocharis S
肝配蛋白（Ephrin，Eph）受体在多种人类恶性肿瘤中频繁过表达，与肿瘤的生长、侵袭、转移和血管生成有关。本研究旨在探讨EphA1、A4、A5和A7蛋白在非小细胞肺癌（NSCLC）中的表达及其临床意义。采用免疫组化方法检测88例手术切除的NSCLC组织芯片中EphA1、A4、A5和A7蛋白的表达，并分析其与临床病理特征和患者生存期的关系。升高的EphA4表达与低组织病理学阶段和炎症的存在显著相关（分别为p = 0.047和p = 0.026）。EphA7表达升高与老年患者的年龄、纤维化的存在和较小的肿瘤大小显著相关（分别为p = 0.036、p = 0.029和p = 0.018）。EphA1、A5和A7表达与肿瘤增殖能力正相关（分别为p = 0.047、p = 0.002和p = 0.046）。升高的EphA4、A5和A7表达在单变量（对数秩检验，分别为0 = 0.019，p = 0.006和p = 0.012）和多变量（Cox回归分析，分别为p = 0.029，p = 0.068和p = 0.044）水平上被鉴定为有利患者存活的预测因子。本研究支持Eps可能参与肺癌进展的证据，加强了其作为患者管理和预后的临床生物标志物的实用性，以及作为未来治疗干预的潜在靶点。
Ephrin (Eph) receptors are frequently overexpressed in a wide variety of human malignant tumors, being associated with tumor growth, invasion, metastasis and angiogenesis. The present study aimed to evaluate the clinical significance of EphA1, A4, A5 and A7 protein expression in non-small cell lung carcinoma (NSCLC). EphA1, A4, A5 and A7 protein expression was assessed immunohistochemically in tissue microarrays of 88 surgically resected NSCLC and was analyzed in relation with clinicopathological characteristics and patients’ survival. Elevated EphA4 expression was significantly associated with low histopathological stage and presence of inflammation (p = 0.047 and p = 0.026, respectively). Elevated EphA7 expression was significantly associated with older patients’ age, presence of fibrosis and smaller tumor size (p = 0.036, p = 0.029 and p = 0.018, respectively). EphA1, A5 and A7 expression were positively associated with tumor proliferative capacity (p = 0.047, p = 0.002 and p = 0.046, respectively). Elevated EphA4, A5 and A7 expression were identified as predictors of favourable patients’ survival at both univariate (Log-rank test, 0 = 0.019, p = 0.006 and p = 0.012, respectively) and multivariate levels (Cox-regression analysis, p = 0.029, p = 0.068 and p = 0.044, respectively). The present study supported evidence that Ephs may be involved in lung cancer progression, reinforcing their utility as clinical biomarkers for patients’ management and prognosis, as also as potential targets for future therapeutic interventions.